| Trial ID: | L4178 |
| Source ID: | NCT00833716
|
| Associated Drug: |
Semaglutide
|
| Title: |
Effect of Renal Impairment on the Pharmacokinetics of NN9535
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2|Renal Impairment
|
| Interventions: |
DRUG: semaglutide
|
| Outcome Measures: |
Primary: AUC of NN9535, at 21 days | Secondary: Laboratory safety, adverse events, at 21 days
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
62
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2009-02-02
|
| Completion Date: |
2010-07-26
|
| Results First Posted: |
|
| Last Update Posted: |
2017-04-04
|
| Locations: |
Novo Nordisk Investigational Site, Miami, Florida, 33014, United States|Novo Nordisk Investigational Site, Orlando, Florida, 32806, United States|Novo Nordisk Investigational Site, Knoxville, Tennessee, 37920, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00833716
|
